19 completed, 11 terminated, 3 unknown, 2 withdrawn. 36 Phase 2, 6 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 36 | Completed 19, Terminated 11, Unknown 3, Withdrawn 2, Active not recruiting 1 |
| Phase 1 | 6 | Completed 4, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Protein expression analysis: new trials by email Literature Review of Protein expression analysis trials Research Report on Protein expression analysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brivanib Metastatic Renal Cell Carcinoma Brivanib alaninate, Polymerase chain reaction, Iodine I 124 chimeric monoclonal antibody G250 - Renal Cell Carcinoma | Phase 2 | Terminated | Abramson Cancer Center at Penn Medicine | 10 | 2011-11-01 | 2021-04-13 |
| Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors Tamoxifen Citrate, Placebo, Digital mammography - Breast Cancer | Phase 2 | Active not recruiting | University of Alabama at Birmingham | 84 | 2010-09-01 | 2026-01-05 |
| Temozolomide in Treating Patients With Invasive Pituitary Tumors temozolomide, DNA methylation analysis, microarray analysis - Brain and Central Nervous System Tumors | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2009-12-01 | 2020-07-31 | |
| Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer bevacizumab, cetuximab, fluorouracil - Colorectal Cancer | Phase 2 / Phase 3 | Completed | Medical Research Council | 3240 | 2009-07-01 | 2013-12-19 |
| Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia clofarabine, daunorubicin hydrochloride, cytogenetic analysis - Leukemia | Phase 2 | Terminated | Roswell Park Cancer Institute | 21 | 2008-12-01 | 2016-08-17 |
| PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction - Kaposi's Sarcoma | Phase 1 / Phase 2 | Terminated | AIDS Malignancy Consortium | 17 | 2008-09-01 | 2018-06-06 |
| Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy erlotinib hydrochloride, sorafenib tosylate, DNA analysis - Lung Cancer | Phase 2 | Unknown | Yonsei University | 47 | 2008-09-01 | 2009-08-25 |
| CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7 pegfilgrastim, rituximab, cyclophosphamide - Leukemia | Phase 2 | Completed | Cancer Trials Ireland | 52 | 2008-08-18 | 2025-07-08 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, protein expression analysis - Lung Cancer | Phase 2 | Completed | Greg Otterson | 63 | 2008-08-14 | 2018-04-02 |
| Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer SOD1 inhibitor ATN-224, exemestane, protein expression analysis - Breast Cancer | Phase 2 | Terminated | Cancer Research UK | 111 | 2008-06-01 | 2013-07-10 |
| Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer rucaparib (CO-338; formally AG-014699 or PF-01367338), protein expression analysis, western blotting - brca1 Mutation Carrier, brca2 Mutation Carrier | Phase 2 | Completed | Cancer Research UK | 78 | 2007-12-01 | 2016-05-24 |
| Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer erlotinib hydrochloride, celecoxib, placebo - Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | Phase 2 | Completed | City of Hope Medical Center | 107 | 2007-11-01 | 2017-03-29 |
| Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer bevacizumab, carboplatin, erlotinib hydrochloride - Lung Cancer | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 116 | 2007-10-01 | 2017-06-08 |
| Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery gemcitabine hydrochloride, oxaliplatin, protein expression analysis - Pancreatic Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 39 | 2007-10-01 | 2017-03-16 |
| Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin FOLFOX regimen, fluorouracil, leucovorin calcium - Chemotherapeutic Agent Toxicity, Colorectal Cancer | Phase 2 | Unknown | Institut Cancerologie de l'Ouest | 206 | 2007-09-01 | 2009-07-08 |
| Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer fluorouracil, leucovorin calcium, oxaliplatin - Gastric Cancer | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 33 | 2007-08-01 | 2012-11-01 |
| Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery erlotinib hydrochloride, conventional surgery, immunohistochemistry staining method - Intraductal Papillary Mucinous Neoplasm of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2007-06-01 | 2014-10-16 |
| Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery cisplatin, etoposide, nelfinavir mesylate - Lung Cancer | Phase 1 / Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 55 | 2007-06-01 | 2020-04-24 |
| Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction - Brain and Central Nervous System Tumors | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 47 | 2007-06-01 | 2016-02-29 |
| Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery bevacizumab, dexamethasone, floxuridine - Liver Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 22 | 2007-05-09 | 2024-12-10 |
Showing 20 of 36. Sign in to see all of them.
Breast Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (7) · Lung Neoplasms (6) · Head and Neck Neoplasms (3) · Leukemia (3) · Carcinoma, Renal Cell (2) · Central Nervous System Neoplasms (2) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Rectal Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2)
Memorial Sloan Kettering Cancer Center (4) · Vanderbilt-Ingram Cancer Center (4) · City of Hope Medical Center (3) · Abramson Cancer Center at Penn Medicine (2) · Cancer Research UK (2) · Roswell Park Cancer Institute (2) · University of Medicine and Dentistry of New Jersey (2) · University of Nebraska (2) · AIDS Malignancy Consortium (1) · Cancer Trials Ireland (1) · Centre Hospitalier Universitaire Vaudois (1) · Greg Otterson (1) · Institut Cancerologie de l'Ouest (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1)
United States (26) · United Kingdom (3) · Canada (1) · France (1) · Ireland (1) · South Korea (1) · Switzerland (1)
A. Bapsi Chakravarthy, MD (1) · Adrian L. Harris, MD (1) · Amit Maity (1) · Andrew D. Zelenetz, MD, PhD (1) · Angela Davies, MD (1) · Anthony Heaney, MD (1) · Antonio Omuro, MD (1) · Carlos L. Arteaga, MD (1) · Charles M. Rudin, MD, PhD (1) · David Carbone, M.D., Ph.D. (1) · Donald L. Trump, MD (1) · Eileen O'Reilly, MD (1) · Elisabeth Vandenberghe, MD (1) · Elizabeth C Reed, MD (1) · Elizabeth C. Reed, MD (1)
PMID 14520092, PMID 18090584, PMID 21677464, PMID 23243055, PMID 24901360, PMID 25057165, PMID 26123189, PMID 26898607, PMID 28925785, PMID 31319977, PMID 31436839, PMID 35135810
P30CA033572 (2), P30CA036727 (2), P30CA068485 (2), P30CA072720 (2), 2008 (1), N01CN35160 (1), P30CA006973 (1), P30CA008748 (1), P30CA015083 (1), P50CA098131 (1), R01CA080195 (1), R01CA140245 (1), U01CA121947 (1)